Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sirna Therapeutics Inc.

Division of Alnylam Pharmaceuticals Inc.
www.sirna.com

Latest From Sirna Therapeutics Inc.

Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work

RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.

BioPharmaceutical United States

Deal Watch: Endo Elbows In On Valeant’s Pursuit Of Salix

Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.

BioPharmaceutical Deals

Biopharma Dealmaking Quarterly Statistics, Q1 2014

Biopharma financing totaled $9.8 billion, a 53% increase over Q4 2013. Twenty-two M&As were completed with a combined potential value reaching $31.3 billion, and there were 103 biopharma alliances totaling $1.9 billion in potential pre-commercialization value, down 30% from the previous quarter.

BioPharmaceutical Deals

Deals In Depth: January 2014

Genzyme made a significant investment in RNA interference in a new deal with Alnylam; J&J sold Ortho-Clinical Diagnostics to Carlyle Group for just over $4 billion; biopharma financing reached $2.8 billion in January, more than doubling December’s total; and device companies only raised money privately only in January, mostly from late-stage venture rounds.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ribozyme Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alnylam Pharmaceuticals Inc.
  • Senior Management
  • Gregory Weaver, SVP, CFO
    Barry Polisky, PhD, SVP, Research & CSO
  • Contact Info
  • Sirna Therapeutics Inc.
    Phone: (415) 512-7200
    1700 Owens St.
    4th Floor
    San Francisco, CA 94158
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register